[HTML][HTML] iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova, KS Anufrieva… - Stem Cell Research & …, 2023 - Springer
Background Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova… - Stem cell research …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova, KS Anufrieva… - 2022 - researchsquare.com
Background: Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.
ME Bogomiakova, EK Sekretova… - Stem Cell Research & …, 2023 - europepmc.org
Background Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
[PDF][PDF] iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova… - Stem Cell Research …, 2023 - scholar.archive.org
Background Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.
ME Bogomiakova, EK Sekretova… - Stem Cell Research …, 2023 - search.ebscohost.com
Background: Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
[PDF][PDF] iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova, KS Anufrieva… - researchgate.net
Background: Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-speci c iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-speci c iPSCs makes personalized therapy possible …
[HTML][HTML] iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova… - … Cell Research & …, 2023 - stemcellres.biomedcentral.com
Dozens of transplants generated from pluripotent stem cells are currently in clinical trials.
The creation of patient-specific iPSCs makes personalized therapy possible due to their …
The creation of patient-specific iPSCs makes personalized therapy possible due to their …
[HTML][HTML] iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova… - Stem Cell Research & …, 2023 - ncbi.nlm.nih.gov
Background Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
ME Bogomiakova, EK Sekretova… - Stem Cell Research …, 2023 - search.proquest.com
Background Dozens of transplants generated from pluripotent stem cells are currently in
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …
clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible …